A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.

Gail J. Roboz,Pinkal Desai,Sangmin Lee,Ellen K. Ritchie,Eric S. Winer,Mark DeMario,Barbara J. Brennan,Eveline Nüesch,Evelyne Chesne,Laura Brennan,Katharina Lechner,Martin Kornacker,Daniel J. DeAngelo

A dose escalation study of RO6870810/TEN-10 in patients with acute myeloid leukemia and myelodysplastic syndrome.

2021

Gail J. Roboz
Pinkal Desai
Sangmin Lee
Ellen K. Ritchie
Eric S. Winer
Mark DeMario
Barbara J. Brennan
Eveline Nüesch
Evelyne Chesne
Laura Brennan
Katharina Lechner
Martin Kornacker
Daniel J. DeAngelo

Bromodomain and extra-terminal (BET) proteins can drive carcinogenesis and therapy resistance. RO6870810 (RO) is a novel, small-molecule BET inhibitor. We conducted a study in 32 patients with rela...

Keywords:

Bromodomain
dose escalation
Cancer research
treatment resistance
Carcinogenesis
Myeloid leukemia
in patient
Medicine
BET inhibitor

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations